NPS Pharmaceuticals (NPSP)
NPS Pharmaceuticals Cash and Equivalents: 48.97M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NPSP Cash and Equivalents Rankings
| Overall | 45th percentile | 2321 of 4277 |
| Sector | 59th percentile | 202 of 494 in Healthcare |
| Industry | 58th percentile | 64 of 155 in Biotechnology |
NPSP Cash and Equivalents Range, Past 5 Years
| Minimum | 18.28M | Dec 2009 |
| Maximum | 206.28M | Sep 2007 |
| Average | 78.93M |
About Cash and Equivalents
Cash and equivalents is cash or cash equivalents that a company possesses at any given time. Examples of cash equivalents are: money market accounts, treasury bills, and short term government bonds. Cash and cash equivalents are a business' most liquid assets. Cash on hand results from a positive cash flow statement.
Investors look at cash on hand as a reflection of a company's solvency and liquidity.
Learn More
You may also be interested in these NPSP related companies
NPSP News
NPS Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 29, 4:10PM Business Wire
May 29, 4:10PM Business Wire
RT @TheEquitiesRoom: EBR: Watchlist/worksheet/4 Trading Ideas: $DECK $CRR $NPSP $LOW $V http://stks.co/3wzM < thanks for sharing
about 8 days ago by 1nvestor
about 8 days ago by 1nvestor
$NPSP Close at highs, nice volume too. Can't figure out why this isn't getting more attention.
about 9 days ago by Random_Walk
about 9 days ago by Random_Walk
$NPSP Nice rebound today after yesterday's selloff. Good volume for a change.
about 13 days ago by Random_Walk
about 13 days ago by Random_Walk
$NPSP http://stks.co/3pss Golden Cross, 50MA cross above the 200MA, breakingout the $7.39 resistance, positive momentum
about 16 days ago by gantosj
about 16 days ago by gantosj
ThinkEquity, Canacord, S&P, Needham all have retiterated buy ratings on $NPSP in last week. Very undervalued considering potential here.
about 24 days ago by Random_Walk
about 24 days ago by Random_Walk
$NPSP 200 Day SMA Cross - Price crossed above 200 day SMA (6.8493). Confirmed by volume.
about 27 days ago by TradeIdeasQuant
about 27 days ago by TradeIdeasQuant
$NPSP 200 Day SMA Cross - Price crossed below 200 day SMA (6.8493). Confirmed by volume.
about 27 days ago by TradeIdeasQuant
about 27 days ago by TradeIdeasQuant
Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Awaiting Date for Gattex FDA AdCom Meeting
May 04, 9:25AM Street Insider
May 04, 9:25AM Street Insider
Listen to $NPSP Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3f5z
about 27 days ago by earningscast
about 27 days ago by earningscast
$NPSP No love for $NPSP? Nice breakout today, albeit on low volume. Long from 7.10. Holding. http://chart.ly/2f5qte9
about 33 days ago by Random_Walk
about 33 days ago by Random_Walk
$NPSP http://stks.co/3YQG breaking out the channel testing the upper line and bouncing back, looks good with positive momentum
about 34 days ago by gantosj
about 34 days ago by gantosj
$NPSP Volume perking up. Upcoming catalyst. Approaching breakout. Keep an eye on $NPSP.
about 36 days ago by Random_Walk
about 36 days ago by Random_Walk
$NPSP http://stks.co/3Ogl Trading in a horizontal channel, Bollinger band in a Volatility Squeeze, near term catalyst
about 43 days ago by gantosj
about 43 days ago by gantosj
$NPSP http://stks.co/3LuR consolidating with a move over 7 targetting 7.83, under 6.38 targets 5.50
about 46 days ago by harmongreg
about 46 days ago by harmongreg
$NPSP filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3KmH
about 48 days ago by MarketBrief
about 48 days ago by MarketBrief
NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference
Mar 07, 4:10PM Business Wire
Mar 07, 4:10PM Business Wire
NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors
Feb 29, 8:10AM Business Wire
Feb 29, 8:10AM Business Wire
NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance
Feb 15, 4:30PM Business Wire
Feb 15, 4:30PM Business Wire
NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX
Jan 31, 8:04AM Benzinga
Jan 31, 8:04AM Benzinga
NPS Pharma (NPSP) announces FDA acceptance of NDA for Gattex(R) in adult SBS
Jan 31, 8:04AM Street Insider
Jan 31, 8:04AM Street Insider
Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Shares Undervalued
Jan 06, 10:29AM Street Insider
Jan 06, 10:29AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NPSP | 7.93 | -0.17 | -2.10% | 697.49M |
| NPM | 15.24 | +0.03 | +0.20% | |
| NPK | 66.00 | -0.43 | -0.65% | 457.04M |
| NNBR | 7.68 | -0.39 | -4.83% | 136.79M |
| NNA | 2.585 | -0.01 | -0.19% | 104.95M |
| NMT | 15.12 | -0.11 | -0.71% | |
| NMRX | 8.92 | -0.06 | -0.67% | 136.14M |
| NMR | 3.27 | -0.05 | -1.51% | 12.16B |
| NMM | 13.98 | -0.37 | -2.58% | 672.87M |
| NMD | 12.32 | +0.01 | +0.08% |
